BioTime, Inc. (BTX)
(Delayed Data from AMEX)
$1.26 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.26 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Lineage Cell Therapeutics, Inc. [BTX]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; New Franchise With Important Upcoming Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cashing a Check to Fuel Core Assets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Building Pipeline and Thesis Visibility; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Longer OpRegen Follow-Up and Incremental Update Continue to Point in Right Direction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; Major Focus Now With All Relevant Assets in House; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Time for a Real Look With Welcomed Focus; Initiating at Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for BTX
Provider: ValuEngine, Inc
|